Pancreatic cancer has a low five-year survival rate of about 10 percent as 80 to 85 percent of the patients cannot receive surgery. Therefore, predicting the prognosis of pancreatic cancer patients who cannot undergo surgery is important in determining the treatment policy. The current diagnosis of pancreatic cancer confirms the level of the protein CA19-9 as a tumor marker. However, the prediction of prognosis is inaccurate, and there has been no stronger predictor of prognosis. [/ssubhead]
As patients with this mutant gene are very responsive to specific chemotherapy, the team expects that the new genetic variant will help determine treatment policies. Read more . . .